KR20190089191A - 티로신 유도체 및 이들을 포함하는 조성물 - Google Patents

티로신 유도체 및 이들을 포함하는 조성물 Download PDF

Info

Publication number
KR20190089191A
KR20190089191A KR1020197018473A KR20197018473A KR20190089191A KR 20190089191 A KR20190089191 A KR 20190089191A KR 1020197018473 A KR1020197018473 A KR 1020197018473A KR 20197018473 A KR20197018473 A KR 20197018473A KR 20190089191 A KR20190089191 A KR 20190089191A
Authority
KR
South Korea
Prior art keywords
cancer
tyrosine
methyl
composition
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197018473A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 호프만
Original Assignee
타임, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by 타임, 인크. filed Critical 타임, 인크.
Publication of KR20190089191A publication Critical patent/KR20190089191A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197018473A 2016-11-30 2017-11-30 티로신 유도체 및 이들을 포함하는 조성물 Ceased KR20190089191A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
US15/365,120 2016-11-30
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
KR20190089191A true KR20190089191A (ko) 2019-07-30

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018473A Ceased KR20190089191A (ko) 2016-11-30 2017-11-30 티로신 유도체 및 이들을 포함하는 조성물

Country Status (12)

Country Link
EP (1) EP3548086A1 (https=)
JP (2) JP2019536783A (https=)
KR (1) KR20190089191A (https=)
CN (1) CN110062633A (https=)
AU (1) AU2017368135A1 (https=)
BR (1) BR112019011033A2 (https=)
CA (1) CA3045110A1 (https=)
EA (1) EA201991305A1 (https=)
IL (1) IL266840A (https=)
MX (1) MX2019006326A (https=)
PH (1) PH12019501186A1 (https=)
WO (1) WO2018102506A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
CN115379851A (zh) * 2019-11-07 2022-11-22 因斯瑞拜奥有限公司 使用生长因子抗体与非酪氨酸靶向激酶抑制剂的组合的方法和组合物
WO2021146506A2 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions and methods for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
KR20090014164A (ko) * 2006-04-19 2009-02-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
PL2804599T3 (pl) * 2012-01-17 2019-06-28 Tyme, Inc. Terapia skojarzona do leczenia nowotworu złośliwego
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
AU2017368135A1 (en) 2019-06-13
WO2018102506A1 (en) 2018-06-07
IL266840A (en) 2019-07-31
CA3045110A1 (en) 2018-06-07
EP3548086A1 (en) 2019-10-09
EA201991305A1 (ru) 2019-10-31
JP2022153587A (ja) 2022-10-12
JP2019536783A (ja) 2019-12-19
PH12019501186A1 (en) 2020-02-10
CN110062633A (zh) 2019-07-26
BR112019011033A2 (pt) 2019-10-15
MX2019006326A (es) 2019-07-12

Similar Documents

Publication Publication Date Title
KR102172658B1 (ko) 약학 조성물 및 방법
US8481498B1 (en) Pharmaceutical compositions and methods
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
US20160263198A1 (en) Pharmaceutical compositions and methods
KR20190089191A (ko) 티로신 유도체 및 이들을 포함하는 조성물
KR20190084291A (ko) 암 치료를 위한 제약 조성물 및 방법
US11052068B2 (en) Pharmaceutical compositions and methods
KR20190008557A (ko) 암의 치료에서의 디히드로테스토스테론 및 디히드로테스토스테론 유도체 및 프로모터
CA3157855A1 (en) Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
US20190275117A1 (en) Pharmaceutical Compositions And Methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220504

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220809

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220504

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220809

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220704

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201130

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221201

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221109

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220809

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220704

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20220504

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201130

X601 Decision of rejection after re-examination